The Role of ex-vivo Gene Therapy of Vein Grafts with Egr-1 Decoy in the Suppression of Intimal Hyperplasia

European Journal of Vascular and Endovascular Surgery

Volumn 40, Issue 2, 2010, Pages 216-223

  Peroulis, M ^a,b   Kakisis, J ^a,b   Kapelouzou, A ^a   Giagini, A ^a   Giaglis, S ^a   Mantziaras, G ^a   Kostomitsopoulos, N ^a   Karayannacos, P ^a   MacHeras, A ^b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Decoy; Egr 1; Endothelial cells; Gene therapy; Graft occlusion; Intimal hyperplasia; Vascular

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; KI 67 ANTIGEN; OLIGONUCLEOTIDE; PARAFFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; EX VIVO GENE TRANSFER; EXPERIMENTAL STUDY; GENE EXPRESSION; INTRAOPERATIVE PERIOD; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; STAINING; VEIN GRAFT;

ANIMALS; CAROTID ARTERIES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION; GENETIC THERAPY; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; INTRAOPERATIVE PERIOD; JUGULAR VEINS; MALE; OLIGONUCLEOTIDES; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUNICA INTIMA;

EID: 77955431107     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2010.04.013     Document Type: Article

References (32)

1. A.G.C. Carrel Uniterminal and biterminal venous transplantations Surg Gynecol Obstet 1906 266 286
2. M.L. Neale, J.C. Graham, R.J. Lane, D.S. Cheung, and M. Appleberg The influence of graft type on patency of infrainguinal arterial bypass grafts J Am Coll Surg 178 1994 155 163
3. M.C. Donaldson, J.A. Mannick, and A.D. Whittemore Causes of primary graft failure after in situ saphenous vein bypass grafting J Vasc Surg 15 1992 113 118
4. S. Sarkar, H.J. Salacinski, G. Hamilton, and A.M. Seifalian The mechanical properties of infrainguinal vascular bypass grafts: their role in influencing patency Eur J Vasc Endovasc Surg 31 2006 627 636
5. J.M. Corpataux, J. Naik, K.E. Porter, and N.J. London A comparison of six statins on the development of intimal hyperplasia in a human vein culture model Eur J Vasc Endovasc Surg 29 2005 177 181
6. T. Schachner, Y. Zou, A. Oberhuber, A. Tzankov, T. Mairinger, and G. Laufer Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts Ann Thorac Surg 77 2004 1580 1585
7. J.Y. Jeremy, P. Gadsdon, N. Shukla, V. Vijayan, M. Wyatt, and A.C. Newby On the biology of saphenous vein grafts fitted with external synthetic sheaths and stents Biomaterials 28 2007 895 908
8. A.T. Ulus, U. Tütün, F. Zorlu, C. Can, N. Apaydin, and S. Karacagil Prevention of intimal hyperplasia by single-dose pre-insertion external radiation in canine-vein interposition grafts Eur J Vasc Endovasc Surg 19 2000 456 460
9. S.O. Trerotola, T.J. Carmody, R.D. Timmerman, K.A. Bergan, R.G. Dreesen, and S.V. Frost Brachytherapy for the prevention of stenosis in a canine hemodialysis graft model: preliminary observations Radiology 212 1999 748 754
10. A. Yamaguchi, K.W. Woodburn, M. Hayase, and R.C. Robbins Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model Circulation 102 2000 III275 III280
11. E.J. Wallitt, M. Jevon, and P.I. Hornick Therapeutics of vein graft intimal hyperplasia: 100 years on Ann Thorac Surg 84 2007 317 323
12. T. Schachner Pharmacologic inhibition of vein graft neointimal hyperplasia J Thorac Cardiovasc Surg 131 2006 1065 1072
13. S. Bhardwaj, H. Roy, and S. Ylä-Herttuala Gene therapy to prevent occlusion of venous bypass grafts Expert Rev Cardiovasc Ther 6 2008 641 652
14. V.P. Sukhatme, X.M. Cao, L.C. Chang, C.H. Tsai-Morris, D. Stamenkovich, and P.C. Ferreira A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization Cell 53 1988 37 43
15. E.S. Silverman, and T. Collins Pathways of Egr-1-mediated gene transcription in vascular biology Am J Pathol 154 1999 665 670
16. F. Blaschke, D. Bruemmer, and R.E. Law Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis Rev Endocr Metab Disord 5 2004 249 254
17. T.A. McCaffrey, C. Fu, B. Du, S. Eksinar, K.C. Kent, and H. Bush High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis J Clin Invest 105 2000 653 662
18. K. Ohtani, K. Egashira, M. Usui, M. Ishibashi, K.I. Hiasa, and Q. Zhao Inhibition of neointimal hyperplasia after balloon injury by cis-element 'decoy' of early growth response gene-1 in hypercholesterolemic rabbits Gene Ther 11 2004 126 132
19. T method Methods 25 2001 402 408
20. A.W. Hoel, and M.S. Conte Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass Cardiovasc Drug Rev 25 2007 221 234
21. A. Ehsan, M.D.G. Dell'Acqua, and V.J. Dzau Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after e2f decoy oligonucleotide gene therapy J Thor Cardiovasc Sur 121 2001 714 722
22. M.J. Mann, A.D. Whittemore, M.C. Donaldson, M. Belkin, M.S. Conte, and J.F. Polak Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the prevent single-centre, randomised, controlled trial Lancet 354 1999 1493 1498
23. J.H. Alexander, G. Hafley, R.A. Harrington, E.D. Peterson, T.B. Ferguson Jr., and T.J. Lorenz PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial JAMA 294 2005 2446 2454
24. T. Miyake, M. Aoki, S. Shiraya, K. Tanemoto, T. Ogihara, and Y. Kaneda Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model J Mol Cell Cardiol 41 2006 431 440
25. K. Egashira, J. Suzuki, H. Ito, M. Aoki, M. Isobe, and R. Morishita Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting J Gene Med 10 2008 805 809
26. U. Kelkenberg, A.H. Wagner, J. Sarhaddar, M. Hecker, and H.E. von der Leyen CCAAT/enhancer-binding protein decoy oligodeoxynucleotide inhibition of macrophage-rich vascular lesion formation in hypercholesterolemic rabbits Arterioscler Thromb Vasc Biol 22 2002 949 954
27. J.D. Ahn, R. Morishita, Y. Kaneda, S.J. Lee, K.Y. Kwon, and S.Y. Choi Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo Circ Res 90 2002 1325 1332 (Pubitemid 34787415)
28. M. Kume, K. Komori, T. Matsumoto, T. Onohara, K. Takeuchi, and Y. Yonemitsu Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries Circulation 105 2002 1226 1232
29. T. Miyake, M. Aoki, and R. Morishita Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model Cardiovasc Res 79 2008 706 714
30. M.L. Klyachkin, M.G. Davies, E. Svendsen, J.H. Kim, M.F. Massey, and L. Barber Hypercholesterolemia and experimental vein grafts: accelerated development of intimal hyperplasia and an increase in abnormal vasomotor function J Surg Res 54 1993 451 468
31. J. Norman, W. Denham, D. Denham, J. Yang, G. Carter, and A. Abouhamze Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation Gene Therapy 7 2000 1425 1430
32. D. Eefting, I. Bot, M.R. de Vries, A. Schepers, J.H. van Bockel, and T.J. Van Berkel Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice J Vasc Surg 50 2009 152 160